Navigation Links
Moffitt researchers will be strong participants in American Society of Hematology meeting
Date:12/4/2011

TAMPA, Fla. Dec. 5, 2011 When the American Society of Hematology convenes its 53rd Annual Meeting and Exposition on Dec. 10-13 in San Diego, Calif., researchers from Moffitt Cancer Center will break a new record for Moffitt participants with one plenary presentation, 16 oral presentations and more than 50 poster presentations on new research results in a variety of meeting programs that focus on blood cancer basic science and clinical applications, including bone marrow transplantation and clinical trials results.

ASH, with more than 14,000 international members, is the world's largest professional society concerned with the causes and treatments of disorders affecting the blood; bone marrow; and the immunologic, hemostatic and vascular systems. The society seeks to further blood disease understandings, diagnoses, treatments and prevention by promoting research, clinical care, education, advocacy and training in hematology.

Claudio Anasetti, M.D., chair of Moffitt's Department of Blood & Marrow Transplant, will give a Plenary Session Presentation at 2:05 p.m. Sunday reporting on the results of a phase III study on Graft-Versus-Host Disease that compared the transplantation of blood stem cells and bone marrow transplants from unrelated donors.

Other Moffitt investigators will participate with 16 oral and more than 50 posters presentations on topics including stem cell transplantation and novel clinical trials for Myelodysplastic Syndrome (MDS), leukemia, lymphoma and myeloma. In addition, several Moffitt faculty members will participate as speakers or will chair educational or scientific symposiums during the ASH meeting.

Department of Bone Marrow Transplantation

  • Ghada M. Kunter, M.D., will report on therapeutic conditioning prior to stem cell transplantation in adults with acute lymphoblastic leukemia in first remission.
  • Joseph Pidala, M.D., will discuss allogeneic hematopoietic cell transplantation for preventing grade II-IV Graft-Versus-Host Disease.
  • Rajiv Agarwal, M.D., and Frederick Locke, M.D., will present data from a phase II study examining therapeutic conditioning prior to hematopoietic cell transplantation for acute leukemias and MDS.

MDS and Leukemia researchers

  • P.K. Burnette, Pharm.D., Ph.D., will discuss human telomerase reverse transcription deficiency in MDS.
  • Michal Jaglal, M.D., and Rami S. Komrokji, M.D., will present data on the efficacy of chemotherapy drugs for secondary acute myeloid leukemia following Azanucleosides failure.
  • Komrokji will report on a study examining the inhibitor ARRY-614 in patients with MDS and also on a phase II study on a novel inhibitor for treating thrombocythemia myelofibrosis.
  • Mikkael Sekeres, M.D., and Komrokji will review the final results from a phase II continuation study on lenalidomide and azacitidine in combination for patients with higher risk MDS.
  • Sheng Wei, M.D., Ph.D., will report on a study examining the role of myeloid-derived suppressor cells in the pathogenesis of MDS.

Lymphoma and myeloma researchers

  • Beata Holkova, M.D., and Lubomir Sokol, M.D., Ph.D., will discuss a phase II clinical trial for mantle cell lymphoma and diffuse large B-cell lymphoma.
  • Fengdong Cheng, M.D., and Eduardo Sotomayor, M.D., will present on the role of Histone deacetylase 6 and STAT3 in IL-10 gene expression and immune tolerance mediated by antigen-presenting cells.
  • Hong Wei Wang, M.D., and Sotomayor will share data on Tubastatin A, a selective HDAC6 inhibitor that enhances antigen-presenting cell function and restores the responsiveness of tolerant CD4+ T cells.
  • Bertrand Coiffier, M.D., and Sokol will present an analysis of a phase II study of romidepsin for patients with relapsed or refractory common peripheral T-cell lymphoma subtypes.
  • Burnette will discuss mediation by pro-fibrotic mesenchymal stem cells in the bone marrow niche for cytopenias in large cell granular lymphocytic leukemia.
  • Karrune Woan, B.S., and Sotomayor will report on the role of histone deacetylase 11 (HDAC11) as a regulatory checkpoint of T-cell function.
  • Benjamin Djulbegovic, M.D., Ph.D., will discuss the impact of the National Cancer Institute's "Common Toxicity Criteria and Common Terminology Criteria for Adverse Events on Quality of Treatment-Related Harms Reporting."


'/>"/>
Contact: Michelle Foley
Michelle.Foley@moffitt.org
813-745-1505
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Moffitt Cancer Center researchers find MK1775 active against sarcomas
2. Moffitt Cancer Center researchers find men less willing to be screened for cancer
3. Moffitt Cancer Center researchers unravel biochemical factor important in tumor metastasis
4. Moffitt Cancer Center researchers find regulatory T-cell clue to help prevent GVHD
5. Moffitt Cancer Center researchers find more clues to causes of breast cancer
6. Moffitt researchers find possible key to preventing chemotherapy resistance in ovarian cancer
7. Moffitt Cancer Center researchers use new tool to counter multiple myeloma drug resistance
8. Moffitt Cancer Center and GLG Pharma LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
9. Moffitt Cancer Center and GLG Pharma, LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
10. MU researchers recommend exercise for breast cancer survivors, lymphedema patients
11. NSF awards University of Arizona researchers $530,000 for development of new spectral imager
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... Calibration, qualification, and the appropriate ... and maintaining GMP and USP compliance. In a new webinar from METTLER TOLEDO ... " these requirements are explained. The challenge is to determine how to ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... the release of two biometric time and attendance tracking products: the new NCheck ... software. NCheck Cloud Bio Attendance uses biometric face recognition to enable users to ...
(Date:3/28/2017)... ... March 28, 2017 , ... In ... Self-Funding Success website has recently developed and published an informational resource that addresses ... created based on common inquiries the site’s team of third party administrator (TPA) ...
(Date:3/28/2017)... ... ... A minimally invasive porcelain veneer is increasing in popularity ... Dental Laboratories (NADL) is informing dentists about the benefits of minimally invasive dentistry, ... and technicians that create these veneers. , According to National Board for ...
(Date:3/28/2017)... ... ... Public relations pros work hard to earn placements and build a ... results are clear, much of PR is hard to quantify. Goal-setting and measurement are ... firms should always take an all-inclusive approach that takes both traditional and non-traditional factors ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... This morning,s research on ... The Medicines Co. (NASDAQ: MDCO), Ironwood Pharmaceuticals Inc. ... Supernus Pharmaceuticals Inc. (NASDAQ: SUPN ). ... which is governed by the same governing framework ... industry are wholesalers, retailers, pharmacies, and benefit managers. Learn ...
(Date:3/28/2017)... , March 28, 2017  AcelRx Pharmaceuticals, ... on the development and commercialization of innovative therapies ... that the European Medicines Agency (EMA) has notified ... 30 mcg) Marketing Authorisation Application (MAA) has passed ... MAA is underway. The MAA for ARX-04 (known ...
(Date:3/28/2017)... FRANCISCO , March 28, 2017 ...  is expected to reach a value of USD 4.5 ... Grand View Research, Inc. Proper closure of injured tissues ... structure and function. Postoperative leakages occur in 3% to ... complication. They are responsible for one third of postoperative ...
Breaking Medicine Technology: